Results 1 to 7 of 7

Thread: Zinbryta pulled from market World Wide

  1. #1
    Distinguished Community Member Cherie's Avatar
    Join Date
    Oct 2006
    Location
    Southeastern NE
    Posts
    1,461

    Default Zinbryta pulled from market World Wide

    https://www.medpagetoday.com/neurolo...eun=g378374d0r

    Please read the information in the link for more detail. Apparently Daclizumab (Zinbryta) has been found to cause encephalitis and meningitis and like infections and has been pulled voluntarily World Wide from the MS Treatment arena.

  2. The following 8 users say "thanks"


  3. #2
    Distinguished Community Member Sunshine's Avatar
    Join Date
    Oct 2006
    Posts
    3,510

    Default

    Thank you. Such terrible news for people affected by this side effect.

  4. The following 5 users say "thanks"


  5. #3
    Distinguished Community Member
    Join Date
    Oct 2006
    Location
    North Carolina
    Posts
    3,996

    Default

    Bad news. Just glad it was no more widely used than it was. If it had been there would be SO many people effected.
    Virginia

  6. The following 6 users say "thanks"


  7. #4
    Distinguished Community Member agate's Avatar
    Join Date
    Oct 2006
    Location
    USA
    Posts
    7,664
    Blog Entries
    12

    Default

    Thank you for posting this, Cherie.

    Things weren't looking good for Zinbryta last July.

    https://www.fiercepharma.com/pharma/...arket-heats-up

    A terrible shame for those who've been taking Zinbryta.
    Last edited by agate; 03-02-2018 at 01:43 PM.
    MS diagnosed 1980. Avonex 2002-2005. Copaxone 6/07 - 5/10.
    Member of this MS board since 2001.

  8. The following 5 users say "thanks"


  9. #5
    Distinguished Community Member agate's Avatar
    Join Date
    Oct 2006
    Location
    USA
    Posts
    7,664
    Blog Entries
    12
    MS diagnosed 1980. Avonex 2002-2005. Copaxone 6/07 - 5/10.
    Member of this MS board since 2001.

  10. The following 4 users say "thanks"


  11. #6
    Distinguished Community Member agate's Avatar
    Join Date
    Oct 2006
    Location
    USA
    Posts
    7,664
    Blog Entries
    12

    Default

    This editorial in The Lancet (March 17), "End of the road for daclizumab in multiple sclerosis," mentions the rapid development of MS drugs over the last 10 years, pointing out that to survive in this competitive atmosphere, a drug needs to have a very favorable profile:

    http://An editorial in The Lancet (M...{$trackingTag}
    MS diagnosed 1980. Avonex 2002-2005. Copaxone 6/07 - 5/10.
    Member of this MS board since 2001.

  12. The following 4 users say "thanks"


  13. #7
    Distinguished Community Member Cherie's Avatar
    Join Date
    Oct 2006
    Location
    Southeastern NE
    Posts
    1,461

    Default

    I don't think I have talked to a single individual who was taking this medication who was happy with it.

  14. The following 4 users say "thanks"


Similar Threads

  1. Ocrevus doing well on the market
    By agate in forum Multiple Sclerosis
    Replies: 6
    Last Post: 12-05-2017, 12:41 PM
  2. Zinbryta (daclimizumab) "safety action" in EU
    By agate in forum Multiple Sclerosis
    Replies: 3
    Last Post: 07-12-2017, 10:44 AM
  3. Victory at Fresh Market
    By Sunshine in forum Multiple Sclerosis
    Replies: 11
    Last Post: 02-05-2017, 07:43 PM
  4. Daclizumab (Zinbryta) gets FDA approval
    By agate in forum Multiple Sclerosis
    Replies: 15
    Last Post: 05-29-2016, 06:21 AM
  5. basil apex aneurysem.wide neck
    By xmarianne in forum New member introductions
    Replies: 3
    Last Post: 02-20-2013, 04:23 PM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •  


BTC Inc's Disclaimer and Privacy Policy

The material on this site is for information & support purposes only, and is not a substitute for medical advice provided by a licensed health care provider. Always consult your doctor before trying anything that you find online.